Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam

European Journal of Pharmacology

Volumn 342, Issue 2-3, 1998, Pages 127-138

  Nakamura, Kazuo ^a   Kurasawa, Mitsue ^a   Tanaka, Yushiro ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Aniracetam; Apomorphine model; Choice reaction performance task; Delirium; Nefiracetam; Neuroleptic

Indexed keywords

ANIRACETAM; APOMORPHINE; CHOLINERGIC RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; DELIRIUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; ATTENTION; CHOICE BEHAVIOR; CHOLINESTERASE INHIBITORS; DOPAMINE AGONISTS; MALE; MOTOR ACTIVITY; NOOTROPIC AGENTS; PSYCHOMOTOR PERFORMANCE; PYRROLIDINONES; RATS; RATS, WISTAR; TACRINE;

EID: 0032567796     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01457-X     Document Type: Article

References (83)

1. Ahlenius S., Engel J. Effects of a dopamine (DA)-β-hydroxylase inhibitor on timing behaviour. Psychopharmacologia. 24:1972;243-246.
2. Amalric M., Koob G.K. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction time performance in rats. J. Neurosci. 7:1987;2129-2134.
3. 2 dopamine receptor antagonism in a reaction-time task in rats. Neuropsychopharmacology. 8:1993;195-200.
4. Barbeito L., Chéramy A., Godeheu G., Desce J.M., Glowinski J. Glutamate receptors of a quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur. J. Neurosci. 2:1990;304-311.
5. Baunez C., Nieoullon A., Amalric M. Dopamine and complex sensorimotor integration: Further studies in a conditioned motor task in the rat. Neuroscience. 65:1995;375-384.
6. Blass, J.P., Plum, F., 1983. Metabolic encephalopathies in older adults. In: Katzman, R., Terry, R.D. (Eds.), The Neurology of Aging. FA Davis Co, Philadelphia, pp. 189-220.
7. Broks P., Preston G.C., Traub P., Poppleton C., Ward C., Stahl S.M. Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia. 26:1988;685-700.
8. 2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology. 105:1991;335-339.
9. Carli M., Samanin R. Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology. 106:1992;228-234.
10. Carlsson A. Neurotransmitter changes in the aging brain. Dan. Med. Bull. 32(Suppl. 1):1985;40-43.
11. Church W.H., Justice J.B., Neill D.B. Detecting behaviorally relevant changes in extracellular dopamine with microdialysis. Brain Res. 412:1987;397-399.
12. Clow D.W., Jhamandas K. Characterization of L-glutamate action on the release of endogenous dopamine from rat caudate-putamen. J. Pharmacol. Exp. Ther. 248:1988;722-728.
13. Creasey H., Rapoport S.I. The aging human brain. Ann. Neurol. 17:1985;2-10.
14. Crippen D.W. Pharmacologic treatment of brain failure and delirium. Crit. Care Clin. 10:1994;733-766.
15. Cummings J.L., Benson D.F. The role of the nucleus basalis of Meynert in dementia: Review and reconsideration. Alzheimer Dis. Assoc. Disorders. 1:1987;9-18.
16. Devanand D.P., Sackheim I.I.A., Brown R.P., Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch. Neurol. 46:1989;854-857.
17. Factor, S.A., Molho, E.S., Podskalny, G.D., Brown, D., 1995. Parkinson's disease: Drug-induced psychiatric states. In: Weiner, W.J., Lang, A.E. (Eds.), Behavioral Neurology of Movement Disorders. Advances in Neurology, vol. 65. Raven Press, New York, pp. 115-138.
18. 3H ]Aniracetam binds to specific recognition sites in brain membranes J. Neurochem. 65:1995;912-918.
19. Fibiger, H.C., Phillips, A.G., 1979. Dopamine and the neural mechanisms of reinforcement. In: Horn, A.S., Korf, J., Westerink, B.H. (Eds.), The Neurobiology of Dopamine. Academic Press, London, pp. 597-615.
20. Fischer, P., Danielczyk, W., Simanyi, M., Streifler, N.B., 1990. Dopaminergic psychosis in advanced Parkinson's disease. In: Streifler, M.B., Korczyn, A.D., Melamed, E., Youdim, M.B.H. (Eds.), Parkinson's Disease: Anatomy, Pathology and Therapy. Advances in Neurology, vol. 53. Raven Press, New York, pp. 391-397.
21. Foldi N.S., Jutagir R., Davidoff D., Gould T. Selective attention skills in Alzheimer's disease: Performance on graded cancellation tests varying in density and complexity. J. Gerontol. 47:1992;P146-P153.
22. Francis J., Kapoor W. Delirium in hospitalized elderly. J. Gen. Int. Med. 5:1990;65-78.
23. Herrling P. Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: Evidence for its mediation by quisqualate or kainate receptors. Neuroscience. 14:1985;417-426.
24. Hikosaka O. Can we observe attention? Seitai No Kagaku. 46:1995;67-71.
25. Himori N., Mishima K. Amelioration by aniracetam of abnormalities as revealed in choice reaction performance and shuttle behavior. Pharmacol. Biochem. Behav. 47:1994;214-225.
26. Himori N., Watanabe H., Matsuura A., Umeda Y., Kuwahara T., Takemoto C., Takamiya M., Yajima Y., Tanaka Y., Nakamura K. General pharmacological properties of aniracetam, a cerebral insufficiency improver. Jpn. Pharmacol. Ther. 14 (Suppl. 4):1986;93-128.
27. Hiroi N., White N.M. The amphetamine conditioned place preference: Differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. Brain Res. 552:1991;141-152.
28. Hollister L.E. Drug-induced psychiatric disorders and their management. Med. Toxicol. 1:1986;428-448.
29. Imperato A., Tanda G., Frau R., Di Chiara G. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J. Pharmacol. Exp. Ther. 245:1988;257-264.
30. Imperato A., Honoré T., Jensen L.H. Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutaminergic control through non-NMDA receptors: A study in freely-moving rats. Brain Res. 530:1990;223-228.
31. Iversen, S.D., 1977. Brain dopamine systems and behavior. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (Eds.), Handbook of Psychopharmacology, vol. 8. Plenum Press, New York, pp. 334-384.
32. Kawajiri S., Taniguchi K., Sakurai T., Kojima H., Yamasaki T. Effect of DM-9384 on extracellular acetylcholine in the rat frontal cortex measured with microdialysis. Eur. J. Pharmacol. 183:1990;928.
33. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
34. 1 receptor antagonist SCH23390 increases cocaine self-administration in the rat. Neurosci. Lett. 79:1987;315-320.
35. Kubota A., Kurasawa M., Furuya I. Pharmacological study on aniracetam. I. Choice reaction time-shortening action of aniracetam in aged rats. (1): Effective doses and reference drugs. Jpn. Pharmacol. Ther. 14 (Suppl.4):1986;47-54.
36. Kubota A., Furuya I., Kurasawa M. Pharmacological study on aniracetam. III. Choice reaction time-shortening action of aniracetam in rat post-cerebrovascular disease deficiency model-SHR-SP. Jpn. Pharmacol. Ther. 14 (Suppl.4):1986;63-66.
37. Kuczenski R., Segal D.S., Manley L.D. Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates. J. Neurochem. 54:1990;1492-1499.
38. Le Moal M., Simon H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol. Rev. 71:1991;155-234.
39. Lipowski, Z.J., 1990a. Clinical feature, course and outcome. In: Lipowski, Z.J. (Ed.), Delirium: Acute Confusional States. Oxford University Press, New York, pp. 54-70.
40. Lipowski, Z.J., 1990b. Vascular Diseases. In: Lipowski, Z.J. (Ed.), Delirium: Acute Confusional States. Oxford University Press, New York, pp. 375-398.
41. Ljungberg T., Apicella P., Schltz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J. Neurophysiol. 67:1992;145-163.
42. Martin J.R., Haefely W.E. Pharmacology of aniracetam, a novel pyrrolidinone derivative with cognition enhancing activity. Drug Invest. 5(Suppl.1):1993;4-49.
43. Marrow L., Overton P., Clark D. Distribution of conditioned reaction time performance by dopamine receptor antagonists in the rat. Behav. Pharmacol. 4:1993;15-28.
44. Marsden C.D. Dopamine and basal ganglia disorders in human. Semin. Neurosci. 4:1992;171-178.
45. McKenzie J.S., Shafton A.D., Stewart C.A. Intrastriatal dopaminergic agents, muscarinic stimulation and GABA antagonism compared for rotation response in rats. Behav. Brain. Res. 45:1991;163-170.
46. Nabeshima T., Nakayama S., Ichihara K., Yamada K., Shiotani T., Hasegawa T. Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task. Eur. J. Pharmacol. 255:1994;57-65.
47. Nakamura, K., Kurasawa, M., Tanaka, Y., 1998. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Dev. Res., in press.
48. Nakanishi S., Masu M. Molecular diversity and functions of glutamate receptors. Annu. Rev. Biophys. Biomol. Struct. 23:1994;319-348.
49. Otomo E., Hirai S., Hasegawa K., Araki G., Nishimura T., Inanaga K. Usefulness of aniracetam for cerebrovascular disorders: Double-blind trial against Ca hopantenate. J. Clin. Exp. Med. (Igaku No Ayumi). 140:1987;989-1016.
50. Otomo E., Hirai S., Terashi A., Hasegawa K., Tazaki Y., Araki G., Itoh E., Nishimura T., Furukawa T. Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Double-blind trial against placebo. Igaku No Ayumi. 156:1991;143-187.
51. Perschak H., Cuénod M. In vivo release of endogenous glutamate and aspartate in the rat striatum during stimulation of the cortex. Neuroscience. 35:1990;283-287.
52. Petkov V.D., Grahovska T., Petkov V.V., Konstantinova E., Stancheva S. Changes in the brain biogenic monoamines of rats, induced by piracetam and aniracetam. Acta Physiol. Pharmacol. Bulg. 10:1984;6-15.
53. Pietrusiak N., Vincent G.P., Harney R., Sepinwall J. Use of proximal versus distal cues in a water maze task is strain dependent: Aniracetam (Ro13-5057) reverses distal cue deficits. Soc. Neurosci. Abstr. 12:1986;705.
54. Pizzi M., Fallacara C., Arrighi V., Memo M., Spano P. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J. Neurochem. 61:1993;683-689.
55. Pizzi M., Consolandi O., Memo M., Spano P. Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. Eur. J. Neurosci. 8:1996;1516-1521.
56. Posner M.I. Attention: The mechanisms of consciousness. Proc. Natl. Acad. Sci. USA. 91:1994;7398-7403.
57. Robbins, T.W., Brown, V.J., 1990. The role of the striatum in the mental chronometry of action: A theoretical review. In: Huston, J.P., Jones, J.P. (Eds.), Reviews in Neuroscience, vol. 2. Freund, pp. 181-213.
58. Roth R.H. Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Commun. Psychopharmacol. 3:1979;429-445.
59. Ruzicka W., Roth J., Spackova N., Mecir P., Jech R. Apomorphine induced cognitive changes in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;998-1001.
60. Sacaan A.I., Bymaster F.P., Schoepp D.D. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J. Neurochem. 59:1992;245-251.
61. Salamone J.D., Keller R.W., Zigmond M.J., Stricker E.M. Behavioral activation in rats increases striatal dopamine metabolism measured by dialysis perfusion. Brain Res. 487:1989;215-224.
62. Salamone J.D., Steinpreis R.E., McCullough L.D., Smith P., Grebel D., Mahan K. Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology. 104:1991;515-521.
63. Saletu B., Grünberger J. Cerebral hypoxic hypoxidosis: Neurophysiological, psychometric and pharmacotherapeutic aspects. Adv. Biol. Psychiatry. 13:1983;146-164.
64. Saletu B., Grünberger J., Linzmayer L. Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro13-5057-a cerebral insufficiency improver. Methods Find. Exp. Clin. Pharmacol. 2:1980;269-285.
65. Santucci V., Fournier M., Worms P., Keane P., Bizière K. Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 340:1989;93-100.
66. Sarter M. Neuronal mechanisms of attentional dysfunction in senile dementia and schizophrenia: Two sides of the same coin? Psychopharmacology. 114:1994;539-550.
67. Schwam E., Keim K., Cumin R., Gamzu E., Sepinwall J. The effects of aniracetam on primate behavior and EEG. Ann. N.Y. Acad. Sci. 444:1985;482-484.
68. Senin U., Parnetti L., Cucinotta D., Criscuolo D., Longo A., Marini G. Clinical experience with aniracetam in the treatment of senile dementia of the Alzheimer's type and related disorders. Drug Invest. 5 (Suppl. 1):1993;96-105.
69. Simpkins J.W., Millard W.J. Influence of age on neurotransmitter function. Endocrinol. Metab. Clin. 16:1987;893-917.
70. Skirboll L.R., Grace A.A., Bunney B.S. Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists. Science. 206:1979;80-82.
71. Smith I.D., Beninger R.J. Contralateral turning caused by metabotropic glutamate receptor stimulation in the dorsal striatum is reversed by MCPG, TTX and cis-flupenthixol. Behav. Neurosci. 110:1996;282-289.
72. Smith I.D., Todd M.J., Beninger R.J. Glutamate receptor agonist injections into the dorsal striatum cause contralateral turning in the rat: Involvement of kainate and AMPA receptors. Eur. J. Pharmacol. 301:1996;7-17.
73. Steckler T., Inglis W., Winn P., Sahgal A. The pedunculopontine tegmental nucleus: A role in cognitive processes? Brain Res. Rev. 19:1994;298-318.
74. Strömbom U.H. Catecholamine receptor agonists. Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn Schmiedebergs Arch. Pharmacol. 292:1976;167-172.
75. Tissari A.H., Lillgals M.S. Reduction of dopamine synthesis inhibition by dopamine autoreceptor activation in striatal synaptosomes with in vivo reserpine administration. J. Neurochem. 61:1993;231-238.
76. Uchihashi Y., Kuribara H., Isa Y., Morita T., Sato T. The disruptive effects of ketamine on passive avoidance learning in mice: Involvement of dopaminergic mechanism. Psychopharmacology. 116:1994;40-44.
77. Wang Z., Rebec G.V. Neuronal and behavioral correlates of intrastriatal infusions of amphetamine in freely moving rats. Brain Res. 62:1993;79-88.
78. Watabe S., Yamaguchi H., Ashida S. Effects of DM-9384, a new cognition-enhancing agent, on cholinergic system in rat cortex. Soc. Neurosci. Abstr. 16:1990;137.
79. Watabe S., Yamaguchi H., Ashida S. DM-9384, a new cognition-enhancing agent, increase the turnover of components of the GABAergic system in the rat cerebral cortex. Eur. J. Pharmacol. 238:1993;303-309.
80. Wesnes K., Anand R., Simpson P., Christmas L. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J. Psychopharmacology. 4:1990;219-232.
81. Wise R.A. Neuroleptics and operant behavior: The anhedonia hypothesis. Behav. Brain Sci. 5:1982;39-87.
82. Zigmond R.E., Schwarzschild M., Rittenhouse A.R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 12:1989;415-461.
83. Zivkovic I., Thompson D.M., Bertolino M., Uzunov D., Dibella M., Costa E., Guidotti A. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): A benzothiadiazine derivative that enhances cognition by attenuating DL-α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther. 272:1995;300-309.